| Literature DB >> 22312542 |
Alison Unzeitig1, Anne Kobbermann, Xian-Jin Xie, Jingsheng Yan, David Euhus, Yan Peng, Venetia Sarode, Amy Moldrem, A Marilyn Leitch, Valerie Andrews, Roshni Rao.
Abstract
Introduction. Breast conserving surgery (BCS) requires tumor excision with negative margins. Reexcision rates of 30-50% are reported. Ultrasound localization, intraoperative margin pathology, and specimen mammography have reduced reexcisions, but require new equipment. Cavity shave margin (CSM) is a technique, utilizing existing equipment, that potentially reduces reexcision. This study evaluates CSM reexcision impact. Methods. 522 cancers treated with BCS were reviewed. Patients underwent standard partial mastectomy (SPM) or CSM. Data collected included demographics, pathology, and treatments. Results. 455 SPMs were compared to 67 CSMs. Analysis revealed no differences in pathology, intraductal component, or neoadjuvant chemotherapy. Overall reexcision rate = 43%. Most reexcisions were performed for DCIS at margin. SPMs underwent 213 reexcisions (46.8%), versus 16/67 (23.9%) CSMs (P = 0.0003). Total mastectomy as definitive procedure was performed after more SPMs (P = 0.009). Multivariate analysis revealed CSM, % DCIS, tumor size, and race to influence reexcisions. Conclusions. CSM is a technique that reduces reexcisions and mastectomy rates.Entities:
Year: 2012 PMID: 22312542 PMCID: PMC3265214 DOI: 10.1155/2012/725121
Source DB: PubMed Journal: Int J Surg Oncol ISSN: 2090-1402
Patient, tumor, and therapy factors.
| All patients | Cavity shave margins | Standard PM |
| |
|---|---|---|---|---|
|
| ||||
| Race | ||||
| White | 251 (48.1) | 27 (40.3) | 224 (49.2) | 0.1913 |
| Other | 271 (51.9) | 40 (59.7) | 231 (50.8) | |
| Age at diagnosis | 57 | 58 | 57 | 0.5835 |
| BMI | 29 kg/m2 | 30 kg/m2 | 29 kg/m2 | 0.107 |
| Method tumor detected | ||||
| MMG/ultrasound, Combination, other | 350 (67.0) | 48 (71.6) | 302 (66.4) | 0.4865 |
| BSE, PE | 172 (33.0) | 19 (28.4) | 153 (33.6) | |
|
| ||||
| Histology | ||||
| IDC | 316 (60.5) | 39 (58.2) | 277 (60.9) | 0.6896 |
| Other | 206 (39.5) | 28 (41.8) | 178 (39.1) | |
| Associated LVI | ||||
| Yes | 52 (13.5) | 5 (10.2) | 47 (13.9) | 0.6541 |
| No | 334 (86.5) | 44 (89.8) | 290 (86.1) | |
| ER status | ||||
| Positive | 394 (76.4) | 53 (79.1) | 341 (75.9) | 0.6456 |
| Negative | 122 (23.6) | 14 (20.9) | 108 (24.1) | |
| Her 2 neu status | ||||
| Positive | 89 (17.8) | 10 (15.4) | 79 (18.1) | 0.7282 |
| Negative | 412 (82.2) | 55 (84.6) | 357 (81.9) | |
| DCIS in final specimen | ||||
| Yes | 384 (73.6) | 47 (70.1) | 337 (74.1) | 0.5529 |
| No | 138 (26.4) | 20 (29.9) | 118 (25.9) | |
| % DCIS | ||||
| <25% | 177 (46.1) | 20 (42.6) | 157 (46.6) | 0.6419 |
| >25% | 207 (53.9) | 27 (57.4) | 180 (53.4) | |
|
| ||||
| Neoadjuvant chemo/hormonal Therapy | ||||
| Yes | 57 (10.9) | 9 (13.4) | 48 (10.5) | 0.5276 |
| No | 465 (89.1) | 58 (86.6) | 407 (89.5) | |
| Adjuvant chemo/hormonal Therapy | ||||
| Yes | 205 (39.3) | 29 (43.3) | 176 (38.7) | 0.504 |
| No | 317 (60.7) | 38 (56.7) | 279 (61.3) | |
|
| ||||
| Breast surgery localization | ||||
| Wire | 366 (70.8) | 44 (66.7) | 322 (71.4) | 0.469 |
| No localization | 151 (29.2) | 22 (33.3) | 129 (28.6) |
PM: partial mastectomy; BMI: body mass index; MMG: mammogram; BSE: breast self exam; PE: physician exam; IDC: invasive ductal carcinoma; LVI: lymphovascular invasion; ER: estrogen receptor; Her 2 neu: human epidermal growth factor 2; DCIS: ductal carcinoma insitu; Chemo: chemotherapy.
Statistically significant differences.
| All patients | Cavity shave margins | Standard PM |
| |
|---|---|---|---|---|
| Need for 2nd Operation to Achieve adequate margins? | ||||
| Yes | 229 (43.9) | 16 (23.9) | 213 (46.8) | 0.0003 |
| No | 293 (56.1) | 51 (76.1) | 242 (53.2) | |
| Reason for 2nd operation | ||||
| Positive margin | 117 (52.9) | 4 (25) | 113 (55.1) | 0.0346 |
| Close margin (<2 mm) | 104 (47.1) | 12 (75) | 92 (44.9) | |
| If close, type of tumor at margin | ||||
| DCIS | 70 (65.4) | 9 (75) | 61 (64.2) | 0.5377 |
| Other | 37 (34.6) | 3 (25) | 34 (35.8) | |
| If 2nd operation, was residual tumor present? | ||||
| Yes | 98 (42.8) | 3 (18.8) | 95 (44.6) | 0.0644 |
| No | 131 (57.2) | 13 (81.2) | 118 (55.4) | |
| Mastectomy eventually performed? | ||||
| Yes | 78 (14.9) | 3 (4.5) | 75 (16.5) | 0.0091 |
| No | 444 (85.1) | 64 (95.5) | 380 (83.5) | |
| >2 operations required to clear margins? | ||||
| Yes | 46 (8.8) | 0 (0) | 46 (10.1) | 0.0021 |
| No | 476 (91.2) | 67 (100) | 409 (89.9) |
PM: partial mastectomy; DCIS: ductal carcinoma insitu.
Multivariate analysis.
| Odds ratio (95% CI) |
| |
|---|---|---|
| Race | ||
| White | Reference | |
| Black | 2.075 (1.129–3.815) | 0.0125 |
| Other | 2.367 (1.220–4.589) | |
| Largest clinical diameter (cm) | ||
| Continuous | 1.288 (1.069–1.552) | 0.0250 |
| Shave margins taken | ||
| Yes | 0.229 (0.097–0.537) | 0.0028 |
| No | Reference | |
| Additional margins taken | ||
| Yes | 0.504 (0.292–0.871) | 0.0054 |
| No | Reference | |
| Percentage of DCIS | ||
| <25% | Reference | <0.0001 |
| >25% | 4.655 (2.523–8.589) |
DCIS: ductal carcinoma insitu.
Figure 1Reexcision rates of patients undergoing SPM versus CSM with analysis of residual tumor at reexcision.
Comparison of various studies.
| Preoperative diagnosis of breast cancer |
|
| Number of CSM | Definition of negative margin | Reduction in reexcision |
| |
|---|---|---|---|---|---|---|---|
| Cao et al. [ | Unknown | 126 | N/A | 4–6 | 2 mm | 61/103a | |
| Hewes et al. [ | Yes | 957 | N/A | 4 | 1 mm | 107/196b | |
| Huston et al. [ | Yes | 45 | 49 | 4–6 | 2 mm | 21%c | |
| Jacobson et al. [ | Unknown | 125 | N/A | 4–6 | 2 mm | 61/83d | |
| Marudanayagam et al. [ | Yes | 394 | 392 | 4 | Absence of tumor at resected margin | 6.92%e | <0.01 |
| Rizzo et al. [ | Yes | 121 | 199 | 4–5 | 1 mm | 27.90%f | <0.05 |
| Tengher-Barna et al. [ | Yes | 107 | N/A | 4 | 3 mm | 24/47 g |
CSM: cavity shave margin; PM: partial mastectomy.
a,b,d,gThe overall final shave margin status was histologically negative in said amount of patients with histologically positive lumpectomy margins; therefore, areexcision was avoided in these patients.
cReexcision rate in PM group 38.7% versus 17.7% in CSM group.
eReexcision rate in PM group 12.5% versus 5.58% in CSM group.
fReexcision rate in PM group 85.1% versus 57.2% in CSM group.